|
|
|
|
|
|
|
|
|
|
Abstract
Three phase II studies evaluated trabectedin monotherapy as second-/third-line therapy in patients with refractory/recurrent ovarian cancer
(ROC). ..........Trabectedin given
as a single agent q3w as 3-h infusion is the schedule of choice for the
treatment of ROC, and its efficacy and safety profile favorably compares
with other active salvage treatments.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.